TY - JOUR
T1 - A critical review of the use of carvedilol in ischemic heart disease
AU - Chen-Scarabelli, Carol
AU - Saravolatz, Louis
AU - Murad, Yahya
AU - Shieh, Wen Shi
AU - Qureshi, Waqas
AU - Di Rezze, Justin
AU - Abrencillo, Rodeo
AU - Gardin, Tova
AU - Gidwani, Umesh K.
AU - Saravolatz, Louis
AU - Faggian, Giuseppe
AU - Scarabelli, Tiziano M.
N1 - Funding Information:
The authors declare no relevant affiliations or financial involvement with any organization/entity having financial interest/conflict with the topics discussed in the manuscript. No financial writing assistance was utilized in the production of this manuscript. We wish to thank the St John Guild Foundation and the Medical Education Department of St John Hospital and Medical Center which have provided continuous and most generous financial support to the cardiovascular research carried out at the Center for Heart and Vessel Preclinical Studies based at St John Hospital and Medical Center. Finally, our gratitude goes to Ruth Moore, PhD, for her invaluable help and statistical support.
PY - 2012
Y1 - 2012
N2 - β-Adrenergic receptor antagonists (β-blockers) have been recognized for their cardioprotective properties, prompting use of these pharmacologic agents to become more mainstream in acute myocardial infarction (AMI) and congestive heart failure (CHF). Despite their popularity as a class, the ability to protect the myocardium varies significantly between different agents. Carvedilol is a non-selective β-blocker with α1-adrenergic receptor antagonism properties. It is unique among β-blockers because in addition to improving exercise tolerance and its anti-ischemic properties secondary to a reduction in heart rate and myocardial contractility, carvedilol exerts other beneficial effects including: antioxidant effects; reduction in neutrophil infiltration; apoptosis inhibition; reduction of vascular smooth muscle migration; and improvement of myocardial remodeling post-AMI. These properties, documented in animal models and subsequent clinical trials, are consistent with established evidence demonstrating decreased morbidity and mortality in patients with CHF and post-AMI. This article reviews the role of carvedilol compared with other β-blockers in the treatment of CHF and post-AMI management. Adis
AB - β-Adrenergic receptor antagonists (β-blockers) have been recognized for their cardioprotective properties, prompting use of these pharmacologic agents to become more mainstream in acute myocardial infarction (AMI) and congestive heart failure (CHF). Despite their popularity as a class, the ability to protect the myocardium varies significantly between different agents. Carvedilol is a non-selective β-blocker with α1-adrenergic receptor antagonism properties. It is unique among β-blockers because in addition to improving exercise tolerance and its anti-ischemic properties secondary to a reduction in heart rate and myocardial contractility, carvedilol exerts other beneficial effects including: antioxidant effects; reduction in neutrophil infiltration; apoptosis inhibition; reduction of vascular smooth muscle migration; and improvement of myocardial remodeling post-AMI. These properties, documented in animal models and subsequent clinical trials, are consistent with established evidence demonstrating decreased morbidity and mortality in patients with CHF and post-AMI. This article reviews the role of carvedilol compared with other β-blockers in the treatment of CHF and post-AMI management. Adis
UR - http://www.scopus.com/inward/record.url?scp=84870265067&partnerID=8YFLogxK
U2 - 10.2165/11636090-000000000-00000
DO - 10.2165/11636090-000000000-00000
M3 - Review article
C2 - 23061698
AN - SCOPUS:84870265067
SN - 1175-3277
VL - 12
SP - 391
EP - 401
JO - American Journal of Cardiovascular Drugs
JF - American Journal of Cardiovascular Drugs
IS - 6
ER -